Morgan Stanley raised the firm’s price target on Amrize (AMRZ) to $61 from $60 and keeps an Overweight rating on the shares. Good cash generation, volume growth and margin progression added up to an improved Q3 following a “disappointing” Q2, the analyst tells investors in a post-earnings note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRZ: